These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10945715)

  • 1. Cost-effectiveness of statins.
    Reckless JP
    Curr Opin Lipidol; 2000 Aug; 11(4):351-6. PubMed ID: 10945715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.
    Jacobson TA
    Curr Opin Lipidol; 1997 Dec; 8(6):369-74. PubMed ID: 9412778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debate: at what level of coronary heart disease risk should a statin be prescribed?
    Jackson PR; Ramsay LE
    Curr Opin Lipidol; 2000 Aug; 11(4):357-61. PubMed ID: 10945716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of statins.
    Wierzbicki AS; Reynolds TM
    Heart; 2000 Jun; 83(6):713-4. PubMed ID: 10885942
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipid-lowering for prevention of coronary heart disease: what policy now?
    Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
    Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. At what level of coronary heart disease risk should a statin be prescribed?
    Gaw A; Packard CJ
    Curr Opin Lipidol; 2000 Aug; 11(4):363-7. PubMed ID: 10945717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-lowering therapy for the primary prevention of coronary heart disease.
    Gotto AM
    J Am Coll Cardiol; 1999 Jun; 33(7):2078-82. PubMed ID: 10362217
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Jolain B; Pettitt D
    Clin Ther; 1995; 17(3):572-80. PubMed ID: 7585861
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
    Pickin DM; McCabe CJ; Ramsay LE; Payne N; Haq IU; Yeo WW; Jackson PR
    Heart; 1999 Sep; 82(3):325-32. PubMed ID: 10455083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmaco-economics of hypolipidemic agents: analysis of factors influencing the cost-effectiveness relation].
    Scheen AJ
    Rev Med Liege; 1998 May; 53(5):270-5. PubMed ID: 9689881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study.
    Shepherd J
    Am J Cardiol; 2001 Mar; 87(5A):19B-22B. PubMed ID: 11256845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of coronary heart disease prevention strategies in adults.
    Brown AD; Garber AM
    Pharmacoeconomics; 1998 Jul; 14(1):27-48. PubMed ID: 10182193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic implications of lipid-lowering trials: current considerations in selecting a statin.
    Farmer JA
    Am J Cardiol; 1998 Sep; 82(6A):26M-31M. PubMed ID: 9766345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid lowering and coronary heart disease risk: how appropriate are the national guidelines?
    Forge BH; Briganti EM
    Med J Aust; 2001 Nov; 175(9):471-5. PubMed ID: 11758075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of lipid-lowering agents in stroke and coronary heart disease: pharmacoeconomics.
    Rockson SG
    Curr Atheroscler Rep; 2000 Mar; 2(2):144-50. PubMed ID: 11122738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary heart disease prevention: insights from modelling incremental cost effectiveness.
    Marshall T
    BMJ; 2003 Nov; 327(7426):1264. PubMed ID: 14644970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The health economics of the treatment of hyperlipidemia and hypertension.
    McMurray J
    Am J Hypertens; 1999 Oct; 12(10 Pt 2):99S-104S. PubMed ID: 10555609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering drug therapy in elderly patients.
    Berthold HK; Gouni-Berthold I
    Curr Pharm Des; 2011; 17(9):877-93. PubMed ID: 21418034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
    Grover SA; Coupal L; Paquet S; Zowall H
    Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?
    Grover SA; Ho V; Lavoie F; Coupal L; Zowall H; Pilote L
    Arch Intern Med; 2003 Feb; 163(3):333-9. PubMed ID: 12578514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.